Category Archives: Biotechnology

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here. (Updated - April 3, 2017 6:06 AM EDT)

Cellect Biotechnology Ltd. (NASDAQ: APOP) announced today that it has received a formal notice of Intention to Grant for a patent (Application No. 11751949.6-1466) covering a key method of treatment from the European Patent Office. The allowed claims relate to the engineering of regulatory immune cells with enhanced apoptotic activity to be used for immunomodulation in treating or preventing immune-related disorders.

Earlier this year, Cellect received a Notice of Allowance from the U.S. Patent & Trademark Office for the same patent.

The patent is expected to protect Cellects technology and method when used to treat multiple medical conditions with significant unmet needs, such as diabetes, inflammatory bowel disease, graft-versus-host disease and transplant rejection. The patent covers a segment of cell-based therapeutics that is separate from the one Cellect is currently working in, is relevant to the fast-growing class of immune therapies and Cellect believes may create an opportunity to enhance Cellects pipeline.

Shai Yarkoni, Cellects CEO, commented, Now covering both the U.S. and the EU, this patent is a base for the future commercialization of our global business. Cellect has seven families of patents and patent applications to protect its core assets for enabling stem cell regenerative medicine. With this patent, Cellect has the opportunity to diversify its pipeline and open up new commercialization routes for additional market segments.

Follow this link:
Cellect Biotechnology (APOP) Granted European Patents Protecting Technology in Multiple Indications - StreetInsider.com

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 (neratinib) were presented at the 2017 American Association for Cancer Research Annual Meeting (AACR) that is currently taking place in Washington, D.C. The presentation entitled, Neratinib in HER2 or HER3 mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 basket study, was presented as a plenary session by David Hyman, M.D., Director of Developmental Therapeutics at Memorial Sloan Kettering Cancer Center (MSK), and principal investigator of the trial.

The Phase II SUMMIT basket trial is an open-label, multicenter, multinational study to evaluate the safety and efficacy of PB272 administered daily to patients who have solid tumors with activating HER2 or HER3 mutations. All patients received loperamide (16 mg per day initially) prophylactically for the first cycle of treatment in order to reduce the neratinib-related diarrhea.

Included in the presentation were data on 141 patients enrolled in the neratinib monotherapy arm of the trial, including 124 patients with HER2 mutations and 17 patients with HER3 mutations. This included patients with 21 unique tumor types, with the most common being breast, lung, bladder and colorectal cancer. There were also 30 distinct HER2 and 12 distinct HER3 mutations observed among these patients, with the most frequent HER2 variants involving S310, L755, A755_G776insYVMA and V777.

In the HER2-mutant cohort, clinical responses were observed in tumors with S310, L755, V777, P780_Y781insGSP and A775_G776insYVMA mutations. When stratified by tumor type, responses were observed in patients with breast, cervical, biliary, salivary and non-small-cell lung cancers, which led to cohort expansions in these tumor types. No activity was observed in the HER3-mutant cohort. A more detailed presentation of the data is presented in Table 1 below and a copy of the full presentation is available on the Puma Biotechnology website.

HER2mut

HER2mut

HER2mut

HER2mut

HER2mut

HER2mut

HER3mut

Lung

(95% CI)

rate, n (%)

(95% CI)

20.1

(95% CI)

(0.5--NA)

The neratinib safety profile observed in the SUMMIT study is consistent with that observed previously in metastatic patients with HER2 amplified tumors. With anti-diarrheal prophylaxis and management, diarrhea was not a treatment-limiting side effect in SUMMIT. The interim safety results of the study showed that the most frequently observed adverse event was diarrhea. For the 141 patients enrolled in the neratinib monotherapy arm with safety data available, 31 patients (22%) reported grade 3 diarrhea. The median duration of grade 3 diarrhea for those patients was 2 days. 4 patients (2.8%) permanently discontinued neratinib due to diarrhea and 21 patients (14.9%) temporarily discontinued neratinib due to diarrhea and then restarted after the diarrhea subsided.

Dr. David Hyman stated, "Neratinib showed signs of clinical activity in several of the cohorts in the SUMMIT trial. The safety profile of the drug was manageable and the diarrhea was not treatment-limiting with appropriate prophylaxis and management. We look forward to completing enrollment in the ongoing cohorts in the study and continuing to utilize the basket trial design to explore possible treatment options for these select patient populations.

"The basket-trial design we are utilizing for SUMMIT is enabling us to evaluate the clinical potential of neratinib in patients with specific mutation-types rather than limiting exploration to one tumor type at a time. It is an efficient approach that is generating clinically meaningful information to guide targeted therapy across a broad spectrum of tumor types with HER mutations, including in patients with rare tumors who may not otherwise have access to investigational therapies, said Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology. We are very pleased with the preliminary activity seen with neratinib in the SUMMIT trial. We look forward to advancing this targeted compound into further clinical development in multiple HER2 mutant tumor types, both as monotherapy and in novel combinations."

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidatesPB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Currently, the Company is primarily focused on the development of the oral version of neratinib, and its most advanced drug candidates are directed at the treatment of HER2-positive breast cancer. The Company believes that neratinib has clinical application in the treatment of several other cancers as well, including non-small cell lung cancer and other tumor types that over-express or have a mutation in HER2. Further information about Puma Biotechnology can be found at http://www.pumabiotechnology.com.

Forward-Looking Statements:

This press release contains forward-looking statements, including statements regarding the development of the Companys drug candidates. All forward-looking statements included in this press release involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the fact that the Company has no product revenue and no products approved for marketing; the Company's dependence on PB272, which is still under development and may never receive regulatory approval; the challenges associated with conducting and enrolling clinical trials; the risk that the results of clinical trials may not support the Company's drug candidate claims; even if approved, the risk that physicians and patients may not accept or use the Company's products; the Company's reliance on third parties to conduct its clinical trials and to formulate and manufacture its drug candidates; the Company's dependence on licensed intellectual property; and the other risk factors disclosed in the periodic and current reports filed by the Company with the Securities and Exchange Commission from time to time, including the Company's Annual Report on Form 10-K for the year ended December 31, 2016. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.

Read more:
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non ... - Business Wire (press release)

A Little Vertex Goes a Long Way For Biotechnology - Barron's Barron's Healthcare stocks are the second-best performing, behind just the information technology sector year-to-date. Healthcare stocks have gained 8.3%, while the ... and more »

Originally posted here:
A Little Vertex Goes a Long Way For Biotechnology - Barron's - Barron's

By Elizabeth Johnson

Leading pharmaceutical and biotechnology companies chose INTERPHEX 2017 to launch their newest products, with 20 companies debuting new technology at the pharmaceutical and biotechnology industry trade show held March 21-23 at the Jacob K. Javits Convention Center in New York City.

In its 38th year, INTERPHEX offered attendees a mix of content including more than 104 conference education sessions, INTERPHEX Live discussions, hundreds of exhibits and product launches.

The show experienced attendee growth, compared with 2016, and attributes much of that to its robust program.

INTERPHEX offers its customers the opportunity to bring their entire teams and engage in education for everyone, said Melissa Ashley, senior vice president of INTERPHEX.

She continued, Attendance is free to those who register ahead to support the industry and allow companies full teams to experience all that is happening in the industry.

Having grown and evolved from a regional to a national and international event, INTERPHEX selected New York as its home because the city is a gateway that allows people to come from abroad and because there are a lot of customers in the tri-state area.

INTERPHEX is reflective of the industry advancing to the future, with organizers working to ensure the needs of technology companies are on display.

Still, the biotechnology industry is slower to change than some industries because it is heavily regulated, according to Kate Scott McCorriston, director of marketing and technical content for INTERPHEX.

The regulations mean people need to attend to learn about new guidance and regulations, McCorriston explained.

She added, Young professionals need to attend to learn how to manufacture new products within regulations and cost-effectively.

Unique features such as INTERPHEX Live keep attendees engaged.

Unlike standard panels or lectures or even exhibitor-led education, INTERPHEX Live discussions allow participants to ask questions and engage in a direct dialogue with experts, with sessions taking place out in the open and not far from registration, making it easy for people to join the discussions.

In addition, INTERPHEX organizers solicit customer feedback to make sure they are hitting the mark with show programming.

We ask, who do they want more of and what research do they need? Ashley said.

She continued, Then, we put that information together with feedback from our technical advisory board in order to create the best program we can.

In addition to showcasing the latest technology, the show itself uses a lot of technology to provide the best experience for attendees and exhibitors, including online matchmaking tools pre-show so that attendees can customize their experience and understand who they want to target before they arrive.

The show invested in a lead retrieval tool that helps exhibitors really know who they are talking to as well.

We want people to engage, not just walk up and down the aisles and leave, Ashley explained.

The goal of INTERPHEXs show organizers was to reach more attendees using the technology they had available, and it appears they got their wish, with a positive response to those tools.

INTERPHEX is sponsored by the Parenteral Drug Association (PDA) and brings over 11,500 global industry professionals and more than 625 industry-leading suppliers together to Learn it, Experience it, Procure it annually.

INTERPHEX 2018 will take place April 19-21 at the Javits Center.

View original post here:
20 New Biotechnology Products Debut at INTERPHEX 2017 - TSNN Trade Show News (blog)

March 31, 2017 9:38am NASDAQ:BBC

From Zacks: After being stressed by the twin attacks of higher drug pricing and increased regulatory scrutiny, the biotech sector has made a strong comeback in the first quarter of 2017.

In fact, BioShares Biotechnology Clinical Trials ETF (BBC Free Report) tops the list of the best performing ETFs of the quarter, with impressive returns of about 27.4%. BBC carries a Zacks ETF Rank of 3 or Hold rating with a High risk outlook.

The surge in the fund was largely driven by cheap valuation, robust earnings results and a slew of positive actions taken by the President. In particular, Trump promised to reduce federal regulations by 7580% and streamline the Food & Drug Administration (FDA) approval process. This would make it easier for biotech companies to bring new products to the market. Trumps proposed tax reforms and cash repatriation policy are also supporting the rally (read: Top ETF Stories of Q1 from Wall Street).

Apart from these, encouraging industry trends including the possibility of increased M&A activity, an accelerated pace of innovation, promising drug launches, growing importance of biosimilars, cost-cutting efforts, an aging population, expanding insurance coverage, the growing middle class, an insatiable demand for new drugs, and ever-increasing health care spending are fueling growth in the sector.

Lets take a closer look at the fundamentals of BBC and its performance.

BBC in Focus

This fund has a novel approach to biotechnology investing with exposure to companies that are in the clinical trials stage. This can easily be done by tracking the LifeSci Biotechnology Clinical Trials Index. BBC is a small cap centric fund, having amassed $24.4 million in its asset base. It charges 85 bps in fees per year from investors and trades in light average daily volume of around 14,000 shares.

Holding 70 stocks in its basket, it is widely spread out across various components with none holding more than 3.34% share. Though almost all the stocks in the funds portfolio delivered strong returns, a few were the real stars that more than doubled their size (read: Hit ETFs & Stocks from the Top Sector of February).

Below we have highlighted those five best-performing stocks in the ETF with their respective positions in the funds basket:

Best Performing Stocks of BBC

Esperion Therapeutics Inc. (ESPR Free Report) : The stock has surged about 185% so far this year and carries a Zacks Rank #3 with solid Industry rank in the top 39%. Most of the gains came on hopes of the Food and Drug Administrations (FDA) approval to the cholesterol-lowering medicine bempadoic acid. However, Esperion saw its earnings estimates deteriorating from a loss of $3.46 to a loss of $6.27 for this year over the past 90 days. It also has an unfavorable VGM Style Score of F. ESPR occupies the top spot in the funds basket with 3.3% of the total assets (see: all the Health care ETFs here).

Global Blood Therapeutics Inc. (GBT Free Report) : This stock takes the second position in the funds basket with 2.8% allocation. It has also delivered incredible returns of 169% in the first quarter on rumors of the takeover of a big pharma name like Novo Nordisk (NVO). The stock saw its earnings estimates moving from a loss of $2.89 to a loss of $2.83 for this year over last the 90 days. Further, it belong to a solid Industry with a Zacks Rank in the top 43%. The stock has a Zacks Rank #3 with a VGM Style Score of F.

TG Therapeutics Inc. (TGTX Free Report) : It currently has a Zacks Rank #3 with a VGM Style Score of F. The stock soared nearly 150% in the first quarter with most upside coming after positive study results from its phase 3 clinical trial of treatment for high-risk leukemia patients. However, TG Therapeutics saw negative earnings estimate revision of a nickel for the current year over the past 30 days and has an ugly Zacks Industry rank in the bottom 32%. The stock is the third firm and accounts for 2.7% share in BBC (read: Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs).

Cara Therapeutics Inc. (CARA Free Report) : The stock has been climbing since the start of the year and has gained about 105.5% this quarter on the pending trial results of its lead drug candidate. It hit a new one-year high of $20.90 in the last trading session after the company announced positive results from part A of a phase 2/3 trial for chronic kidney disease-associated pruritus. Cara Therapeutics has a solid Zacks Industry rank in the top 43%. However, it has a Zacks Rank #4 (Sell) with a VGM Style Score of F. The stock occupies the fourth position in the funds portfolio, making up for 2.5% share.

NewLink Genetics Corporation (NLNK Free Report) : This stock takes the seventh spot in the funds basket with 2.2% of assets. It has doubled this quarter but saw negative earnings estimate revision of $1.21 for this year over the past 90 days. NewLink Genetics currently has a Zacks Rank #3 with a VGM Style Score of F and solid Zacks Industry rank in the top 43%.

The BioShares Biotechnology Clinical Trials Fund (NASDAQ:BBC) was unchanged in premarket trading Friday. Year-to-date, BBC has gained 25.75%, versus a 5.59% rise in the benchmark S&P 500 index during the same period.

BBC currently has an ETF Daily News SMART Grade of A (Strong Buy), and is ranked #23 of 36 ETFs in the Health & Biotech ETFs category.

This article is brought to you courtesy of Zacks Research.

Tags: biotech Equity Health Care NASDAQ:BBC Zacks

Categories: NASDAQ:BBC

More here:
BioShares Biotechnology Clinical Trials Fund(NASDAQ:BBC ... - ETF Daily News (blog)

Shares of Cellect Biotechnology Ltd. (APOP) are up more than 44% over the last 5 trading days.

With its shares currently traded on both the NASDAQ and Tel Aviv Stock Exchange, Cellect is the company behind ApoGraft, a breakthrough technology for the isolation of stem cells from any given tissue.

Cellect's ApoGraft technology is aiming to turn stem cell transplants into a simple, safe and cost effective process, reducing the associated severe side effects, such as rejection and many other risks, such as Graft versus Host Disease.

Graft versus Host Disease, a condition in which the transplanted immune cells attack the recipient's cells, is a common complication associated with *allogeneic stem cell transplantation. (*Allogeneic stem cell transplantation involves transferring the stem cells to the recipient from a genetically matched relative or other donor).

The positive results from a clinical trial of ApoGraft that involved 104 healthy donors of blood stem cells reported in February of this year demonstrated that Cellect's ApoGraft is a safe, robust and reproducible process for clinical use.

According to the company, the use of the ApoGraft to process human stem cells for bone marrow transplantation resulted in a significant increase in the death of mature immune cells, primarily T Lymphocytes, without compromising the quantity and quality of stem cells. The process takes only a few hours as compared to days of complex and expansive lab work with traditional methods, is anticipated to be extremely cost effective in comparison to current approaches, and has the potential to significantly reduce the risk of GvHD.

The first blood cancer patient was treated in a phase I/II trial of ApoGraft in February of this year, and on March 27th, the company announced that the first stem cell transplant procedure has been successfully performed.

With the first stem cell transplant procedure being successful, Cellect has received the go-ahead from the independent Data and Safety Monitoring Board for enrolling additional 2 cancer patients for ApoGraft transplantation treatments.

The study is designed to enroll 12 patients.

Key Financials:

- Net loss for the fourth quarter ended December 31, 2016 was $0.75 million or $0.007 per share compared to a net loss of $0.96 million or $0.012 per share in Q4, 2015.

- Cash totaled $8.0 million at December 31, 2016 compared to $3.1 million on December 31, 2015.

- The number of shares outstanding is 107.58 million (Data sourced from Yahoo Finance).

In order to maximize the value of the Company for all stakeholders, Cellect plans to delist from the Tel Aviv Stock Exchange (TASE) in accordance with section 350 to the Israeli Company Law.

Shares of Cellect Biotechnology touched an all-time intra-day high of $13.50 on Mar.27, 2017 on the NASDAQ. The stock closed yesterday's trading at $8.98, up 2.75%.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Read more:
Company Spotlight: Cellect Biotechnology - RTTNews - RTT News

Biotechnology is a top-notch field of study that emerged into the scientific world as a result of revolutions in Biology, Chemistry, Informatics, and Engineering. It is considered to be an applied branch of Biology. Biotechnology helps out this old and respectable field of science keep up with the pace of time and remain competitive in the contemporary world.

With a Master in Biotechnology, students will study the use of living organisms and bioprocesses in technology, engineering, medicine, agriculture and results in all kinds of bioproducts, from genetically modified food to serious cutting-edge devices used to carry out gene therapy. Students in Master in Biotechnology programs may also explore bioinformatics, which is the application of statistics and computer science to the field of molecular biology. Bioinformatics is extremely important for contemporary biological and molecular researches because the data amount there grows by geometric progression and it is necessary to have adequate technology to process it. Bioinformatic methods are widely used for mapping and analyzing DNA and protein samples, as well as for the study of genetics and molecular modeling. Biotechnology and Bioinformatics do a great favour to traditional fields of study, refreshing them with new methods of research, which allows their drastic development, and you can make your contribution with a Master in Biotechnology degree.

Find out about various Master in Biotechnology programs by following the links below. Don't hesitate to send the "Request free information" form to come in contact with the relevant person at the school and get even more information about the specific Master in Biotechnology program you are interested in.

Visit link:
Best Master's Degrees in Biotechnology 2017

Prana Biotechnology Limited (ADR) (NASDAQ:PRAN)

Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) shares have been up over 80% on large volumes. PRAN closed yesterday at $2.48, gapped up to open at $2.95, reached an inter-day high of $4.58, and are now trading around $3.60 for an inter-day gain of over 45%. The nano-cap Australian-based biotech firm has, prior to todays action, an average daily trading volume of just over 59,000 but, by 10:30 AM EST, PRAN shares had already traded over 7.1 million times. A review of news services reveals that no news has been reported by the company or an analyst that could account for todays price action.

Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) is a clinical stage biotechnology firm that develops therapeutic medicines. Prana has developed PBT-2 for the treatment of Alzheimers disease. PBT-2 is currently in a Phase IIa clinical trial. Pranas PBT-2 is also being investigated for applications involving other therapeutic applications including age-related cataracts, Huntington disease, Creutzfeldt-Jakob disease, Motor Neuron disease, age-related macular degeneration, cancers, Parkinsons disease, and other neurodegenerative diseases.

When PRAN is adjusted for dilutive effects, the shares high came in early 2014 when PRAN was trading near $80/share. However, by the end of 2014, PRAN shares would end up down over 74%. Dilution, EPS losses, and weak sales figures have plagued the shares. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) have reported sales of $100,000 every year since 2012 except for 2014 when the company reported a figure of $300,000. EPS losses have been noteworthy. In 2012 the EPS loss for shares holders of PRAN was -$5.00, followed by annual EPS losses of-$6.31, -$8.55, -$3.21, and -$3.98 in 2016. There has also been consistent dilution for PRN shareholders. In 2012 the number of outstanding shares was 800,000 and that number grew annually and in 2016 the number was 1.48 million. Given Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) market cap of only $23 million and its lack of sales, no analysts have reviewed the companys share ratings since 2014.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Marc Anderson is a pseudonym. Marc has a degree in economics and a MSc. in Finance. Marc worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant. View all posts by Marcus Anderson

Visit link:
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) Gains are ... - StockNewsUnion

Technology and biotechnology stocks once again top our list of momentum charts to watch.

Achaogen Inc. AKAO, -2.26% had an important snapback session on Tuesday, gaining $2.12, or 9.7%, to $23.90 on over 2 million shares traded. The move came on news that venture capitalist Robert Duggan disclosed a 5.7% stake in the late-stage biopharmaceutical company. Volume was the strongest on an up-day all year, and the stock has now bounced off rising trendline support after a 10-day pullback from the top of the channel to the bottom. If the stock can get through resistance, which is now up around Tuesdays high at $24.46, it could challenge recent highs around $26.75-$27.75 on the way to the top of the channel at over $30.

Cara Therapeutics Inc. CARA, -7.36% had a nice follow-through on Tuesday, jumping 94 cents, or 5%, to $19.09, on 7.6 million shares traded. The biotech company reported positive results in a trial of a treatment for uremic pruritus, or UP. The stock reached $20.24 intraday, the highest its been since September 2015. It came down in the afternoon and didnt close great, but from the standpoint of the daily pattern as well technicals and volume, the stock looks strong. It has climbed nicely off rising trendline support toward mid-channel in the past two weeks. The stock needs to hold lateral support at around $17.50. A move through Tuesdays high could lead to $23 short-term and $27 intermediate-term.

Kopin Corp. KOPN, -0.24% maker of wearable technologies and display products, had nice action on Tuesday, especially in the afternoon when it ran from about $3.90 to $4.19, backing off a little at the close. Net on the day, it gained 8 cents, or 2%, to $4.11 on strong volume of 643,000 shares. Volume has been strong in general in the past few weeks, indicating possible accumulation, and Tuesday saw the stock edge above its breakout point at around $4.09. Watch for $4.75 and then $5-$5.25 as targets.

Nektar Therapeutics NKTR, -3.93% had a breakout session on Tuesday, up 55 cents, or 2%, to $23.93 on 1.7 million shares. The company announced on Monday it has begun dosing in a Phase 1 study of its new biologic therapy to treat auto-immune diseases and inflammatory disorders. The move broke the stock out of a week-long consolidation zone that followed its nearly 50% gap up on March 20. The move came on only average volume. Nonetheless, watch for a run at $26 short-term.

Western Digital Corp. WDC, +2.90% is on the move. Stock in the data-storage company has been up five days in a row since its March 21 close at $73.22. Investors appear to have been encouraged by Micron Technologys MU, +1.65% strong quarterly forecast late last week, and optimism about memory and storage chip demand. On Tuesday, WDC gained $1.99, or 2.5%, to $80.56, on nearly 4 million shares traded. The stock is right at a lateral resistance level, and a pop through there could get it to $86-$87 and then the channel top near $95.

See Harrys video chart analysis on these stocks.

Harry Boxer is founder of TheTechTrader.com, a live trading room featuring his stock picks, technical market analysis, and live chart presentations.

See more here:
Harry Boxer's five technology and biotechnology stocks to watch ... - MarketWatch

With excellent mechanical and chemical stability, the Kromasil EternityXT materials offer first-rate separation power and loadability for purification from low to high pH. Kromasil EternityXT C8 and C18 materials can operate up to pH 12, making it possible to run basic compounds under extreme conditions to improve purification productivity and reduce costs. These products support discovery, development and production departmental goals in the purification of a low molecular weight pharmaceuticals, peptides and biotechnology products.

The exceptional structure of Kromasil EternityXT C18 and C8 materials makes it possible to regenerate the material in-column, carrying out cleaning in place (CIP) even at 1 M NaOH, if so required. While this high concentration NaOH treatment is a standard in bio chromatography and until now only conceivable with polymer resins, Kromasil EternityXT materials open up the spectrum of purification options as its C8 and C18 materials resist up to 1 M NaOH.

Read the rest here:
Purification of Pharmaceutical and Biotechnology Products with Kromasil EternityXT Stationary Phase - Labmate Online